Sympathoinhibition by atorvastatin in hypertensive patients

Circulation Journal

Volumn 74, Issue 12, 2010, Pages 2622-2626

  Gomes, Marc E ^a   Tack, Cees J ^a   Verheugt, Freek W ^a   Smits, Paul ^a   Lenders, Jacques W M ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Hypertension; Statins; Sympathetic nervous system

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ATORVASTATIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NORADRENALIN; PLACEBO; TRIACYLGLYCEROL;

ADRENERGIC ACTIVITY; ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CATECHOLAMINE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG MEGADOSE; FEMALE; HEART RATE VARIABILITY; HUMAN; HYPERTENSION; MALE; NEUROGRAPHY; POSTGANGLIONIC NERVE; PROSPECTIVE STUDY; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; SYMPATHETIC BLOCKING; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; ANIMALS; BLOOD PRESSURE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; MALE; MIDDLE AGED; NOREPINEPHRINE; PROSPECTIVE STUDIES; PYRROLES; SYMPATHETIC NERVOUS SYSTEM; TIME FACTORS;

EID: 78649712954     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0427     Document Type: Article

References (30)

1. Mancia G, De BG, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187.
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003; 289: 2560-2572.
3. M. The sympathetic system and hypertension. Am J Hypertens 2000; 13: 99S-105S.
4. Grassi G. Role of the sympathetic nervous system in human hypertension. J Hypertens 1998; 16: 1979-1987.
5. Takase B, Takeishi Y, Hirai T, Lee JD, Uzui H, Senda S, et al. Comparative effects of amlodipine monotherapy and combination therapy with betaxolol on cardiac autonomic nervous activity and health-related quality of life in patients with poorly controlled hypertension. Circ J 2008; 72: 764-769.
6. Fu Q, Zhang R, Witkowski S, rbab-Zadeh A, Prasad A, Okazaki K, et al. Persistent sympathetic activation during chronic antihypertensive therapy: A potential mechanism for long term morbidity? Hypertension 2005; 45: 513-521.
7. Mancia G, Grassi G, Giannattasio C, Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 1999; 34: 724-728.
8. Julius S, Nesbitt S. Sympathetic overactivity in hypertension: A moving target. Am J Hypertens 1996; 9: 113S-120S.
9. Pliquett RU, Cornish KG, Peuler JD, Zucker IH. Simvastatin normalizes Autonomic neural control in experimental heart failure. Circulation 2003; 107: 2493-2498.
10. Kishi T, Hirooka Y, Mukai Y, Shimokawa H, Takeshita A. Atorvastatin causes depressor and sympatho-inhibitory effects with upregulation of nitric oxide synthases in stroke-prone spontaneously hypertensive rats. J Hypertens 2003; 21: 379-386.
11. Szramka M, Harriss L, Ninnio D, Windebank E, Brack J, Skiba M, et al. The effect of rapid lipid lowering with atorvastatin on autonomic parameters in patients with coronary artery disease. Int J Cardiol 2007; 117: 287-291.
12. Gao L, Wang W, Li YL, Schultz HD, Liu D, Cornish KG, et al. Simvastatin therapy normalizes sympathetic neural control in experimental heart failure: Roles of angiotensin II type 1 receptors and NAD(P)H oxidase. Circulation 2005; 112: 1763-1770.
13. Patel KP, Li YF, Hirooka Y. Role of nitric oxide in central sympathetic outflow. Exp Biol Med 2001; 226: 814-824.
14. Hirooka Y, Sagara Y, Kishi T, Sunagawa K. Oxidative stress and central cardiovascular regulation: Pathogenesis of hypertension and therapeutic aspects. Circ J 2010; 74: 827-835.
15. Wallin BG, Fagius J. Peripheral sympathetic neural activity in conscious humans. Annu Rev Physiol 1988; 50: 565-576.
16. Hryniewicz K, Androne AS, Hudaihed A, Katz SD. Partial reversal of cachexia by beta-adrenergic receptor blocker therapy in patients with chronic heart failure. J Card Fail 2003; 9: 464-468.
17. Grassi G, Seravalle G, Dell'Oro R, Trevano FQ, Bombelli M, Scopelliti F, et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: Results of the CROSS study. J Hypertens 2003; 21: 1761-1769.
18. Mano T, Iwase S, Toma S. Microneurography as a tool in clinical neurophysiology to investigate peripheral neural traffic in humans. Clin Neurophysiol 2006; 117: 2357-2384.
19. Grassi G, Seravalle G, Cattaneo BM, Lanfranchi A, Vailati S, Giannattasio C, et al. Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation 1995; 92: 3206-3211.
20. Willemsen JJ, Ross HA, Jacobs MC, Lenders JW, Thien T, Swinkels LM, et al. Highly sensitive and specific HPLC with fluorometric detection for determination of plasma epinephrine and norepinephrine applied to kinetic studies in humans. Clin Chem 1995; 41: 1455-1460.
21. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: Standards of measurement, physiological interpretation and clinical use. Circulation 1996; 93: 1043-1065.
22. Sinski M, Lewandowski J, Ciarka A, Bidiuk J, Abramczyk P, Dobosiewicz A, et al. Atorvastatin reduces sympathetic activity and increases baroreceptor reflex sensitivity in patients with hypercholesterolaemia and systemic arterial hypertension. Kardiol Pol 2009; 67: 613-620.
23. Vaz M, Jennings G, Turner A, Cox H, Lambert G, Esler M. Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects. Circulation 1997; 96: 3423-3429.
24. Pliquett RU, Cornish KG, Zucker IH. Statin therapy restores sympathovagal balance in experimental heart failure. J Appl Physiol 2003; 95: 700-704.
25. Golomb BA, Dimsdale JE, White HL, Ritchie JB, Criqui MH. Reduction in blood pressure with statins: Results from the UCSD Statin Study, a randomized trial. Arch Intern Med 2008; 168: 721-727.
26. Strazzullo P, Kerry SM, Barbato A, Versiero M, D'Elia L, Cappuccio FP. Do statins reduce blood pressure? A meta-analysis of randomized, controlled trials. Hypertension 2007; 49: 792-798.
27. Patel MB, Stewart JM, Loud AV, Anversa P, Wang J, Fiegel L, et al. Altered function and structure of the heart in dogs with chronic elevation in plasma norepinephrine. Circulation 1991; 84: 2091-2100.
28. Mancia G. The sympathetic nervous system in hypertension (Bjorn Folkow Award Lecture). J Hypertens 1997; 15: 1553-1565.
29. Jamerson KA, Smith SD, Amerena JV, Grant E, Julius S. Vasoconstriction with norepinephrine causes less forearm insulin resistance than a reflex sympathetic vasoconstriction. Hypertension 1994; 23: 1006-1011.
30. Ishikawa T, Mizuno K, Nakaya N, Ohashi Y, Tajima N, Kushiro T, et al. The relationship between the effect of pravastatin and risk factors for coronary heart disease in Japanese patients with hypercholesterolemia. Circ J 2008; 72: 1576-1582.